Glen J. Weiss

Glen J. Weiss

Auto-generated profile, based on publicly available information

Glen J. Weiss

Translational Genomics Research Institute, Neurogenomics Division, Phoenix, AZ 85004, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
KFKristen M. Foss
Kristen M. Foss
CSChao Sima
Chao Sima
DUDonatella Ugolini
Donatella Ugolini
MNMonica Neri
Monica Neri
KAKristi E. Allen
Kristi E. Allen
GWGlen J. Weiss
Glen J. Weiss

27 February 2008 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
GWG. J. Weiss
G. J. Weiss
LBLynne Bemis
Lynne Bemis
ENE. Nakajima
E. Nakajima
MSM. Sugita
M. Sugita
DBD. K. Birks
D. K. Birks
WFW. A. Franklin
W. A. Franklin
Background: Allelic loss in chromosome 3p is one of the most frequent and earliest genetic events in lung carcinogenesis. We investigated if the loss of microRNA-128b, a microRNA located on chromosome 3p and a putative regulator of epidermal growth factor receptor (EGFR), correlated with response to targeted EGFR inhibition. Loss of microRNA-128b would be equivalent to losing a tumor suppressor gene because it would allow increased expression of EGFR. Patients and Methods: We initially showed that microRNA-128b is a regulator of EGFR in non-small-cell lung cancer (NSCLC) cell lines. We tested microRNA-128b expression levels by quantitative RT–PCR, genomic copy number by quantitative PCR, and mutations in the mature microRNA-128b by sequencing. We determined whether microRNA-128b loss of heterozygosity (LOH) in 58 NSCLC patient samples correlated with response to gefitinib and evaluated EGFR expression and mutation status. Results: We determined that microRNA-128b directly regulates EGFR. MicroRNA-128b LOH was frequent in tumor samples and correlated significantly with clinical response and survival following gefitinib. EGFR expression and mutation status did not correlate with survival outcome. Conclusion: Identifying microRNA regulators of oncogenes could have far-reaching implications for lung cancer patients including improving patient selection for targeted agents, development of novel therapeutics, or development as early biomarkers of disease.

1 May 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
GWGlen J. Weiss
Glen J. Weiss
JIJeffrey R. Infante
Jeffrey R. Infante
ECE. Gabriela Chiorean
E. Gabriela Chiorean
MBMitesh J. Borad
Mitesh J. Borad
JBJohanna C. Bendell
Johanna C. Bendell
HBHoward A. Burris
Howard A. Burris
Purpose: The objectives of this phase 1, first-in-human study were to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), safety, pharmacokinetics, and preliminary activity of the hypoxia-activated prodrug TH-302 in patients with advanced solid tumors. Experimental Design: TH-302 was administered intravenously over 30 to 60 minutes in two regimens: three times weekly dosing followed by 1 week off (arm A) and every 3-week dosing (arm B). Results: Fifty-seven patients enrolled (arm A: N = 37 and arm B: N = 20). The TH-302 dose was escalated from 7.5 to 670 mg/m2 in arm A and from 670 to 940 mg/m2 in arm B. The most common adverse events were nausea, skin rash, fatigue, and vomiting. Hematologic toxicity was mild and limited. Grade 3 skin and mucosal toxicities were dose limiting at 670 mg/m2 in arm A; the MTD was 575 mg/m2. In arm B, grade 3 fatigue and grade 3 vaginitis/proctitis were dose limiting at 940 mg/m2; the MTD was 670 mg/m2. Plasma concentrations of TH-302 and the active metabolite Br-IPM (brominated version of isophosphoramide mustard) increased proportionally with dose. Two partial responses were noted in patients with metastatic small cell lung cancer (SCLC) and melanoma in arm A at 480 and 670 mg/m2. Stable disease was observed in arms A and B in 18 and 9 patients, respectively. Conclusions: The MTD of TH-302 was 575 mg/m2 weekly and 670 mg/m2 every 3 weeks. Skin and mucosal toxicities were DLTs. On the basis of responses in metastatic melanoma and SCLC, further investigations in these indications were initiated. Clin Cancer Res; 17(9); 2997–3004. ©2011 AACR.

20 January 2011 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
SAShilpi Arora
Shilpi Arora
ARAarati R. Ranade
Aarati R. Ranade
NTNhan L. Tran
Nhan L. Tran
SNSara Nasser
Sara Nasser
SSShravan Sridhar
Shravan Sridhar
GWGlen J. Weiss
Glen J. Weiss
Brain metastasis (BM) can affect ∼ 25% of nonsmall cell lung cancer (NSCLC) patients during their lifetime. Efforts to characterize patients that will develop BM have been disappointing. microRNAs (miRNAs) regulate the expression of target mRNAs. miRNAs play a role in regulating a variety of targets and, consequently, multiple pathways, which make them a powerful tool for early detection of disease, risk assessment, and prognosis. We investigated miRNAs that may serve as biomarkers to differentiate between NSCLC patients with and without BM. miRNA microarray profiling was performed on samples from clinically matched NSCLC from seven patients with BM (BM+) and six without BM (BM−). Using t‐test and further qRT‐PCR validation, eight miRNAs were confirmed to be significantly differentially expressed. Of these, expression of miR‐328 and miR‐330‐3p were able to correctly classify BM+ vs. BM− patients. This classifier was used on a validation cohort (n = 15), and it correctly classified 12/15 patients. Gene expression analysis comparing A549 parental and A549 cells stably transfected to over‐express miR‐328 (A549‐328) identified several significantly differentially expressed genes. PRKCA was one of the genes over‐expressed in A549‐328 cells. Additionally, A549‐328 cells had significantly increased cell migration compared to A549 cells, which was significantly reduced upon PRKCA knockdown. In summary, miR‐328 has a role in conferring migratory potential to NSCLC cells working in part through PRKCA and with further corroboration in additional independent cohorts, these miRNAs may be incorporated into clinical treatment decision making to stratify NSCLC patients at higher risk for developing BM.

1 August 2010 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PDF file
ARAarati R. Ranade
Aarati R. Ranade
DCDavid Cherba
David Cherba
SSShravan Sridhar
Shravan Sridhar
PRPatrick Richardson
Patrick Richardson
CWCraig Webb
Craig Webb
GWGlen J. Weiss
Glen J. Weiss

4 May 2013 in BMC Genomics
Verified
Journal Article
Open access
PDF file
ACAlexis Christoforides
Alexis Christoforides
JCJohn D Carpten
John D Carpten
GWGlen J Weiss
Glen J Weiss
MDMichael J Demeure
Michael J Demeure
DHDaniel Douglas Von Hoff
Daniel Douglas Von Hoff
DCDavid W Craig
David W Craig
Background: The field of cancer genomics has rapidly adopted next-generation sequencing (NGS) in order to study and characterize malignant tumors with unprecedented resolution. In particular for cancer, one is often trying to identify somatic mutations – changes specific to a tumor and not within an individual’s germline. However, false positive and false negative detections often result from lack of sufficient variant evidence, contamination of the biopsy by stromal tissue, sequencing errors, and the erroneous classification of germline variation as tumor-specific. Results: We have developed a generalized Bayesian analysis framework for matched tumor/normal samples with the purpose of identifying tumor-specific alterations such as single nucleotide mutations, small insertions/deletions, and structural variation. We describe our methodology, and discuss its application to other types of paired-tissue analysis such as the detection of loss of heterozygosity as well as allelic imbalance. We also demonstrate the high level of sensitivity and specificity in discovering simulated somatic mutations, for various combinations of a) genomic coverage and b) emulated heterogeneity. Conclusion: We present a Java-based implementation of our methods named Seurat, which is made available for free academic use. We have demonstrated and reported on the discovery of different types of somatic change by applying Seurat to an experimentally-derived cancer dataset using our methods; and have discussed considerations and practices regarding the accurate detection of somatic events in cancer genomes. Seurat is available at https://sites.google.com/site/seuratsomatic.